4.23.15 The Minnesota Ovarian Cancer Alliance has stepped up our commitment to ovarian cancer research funding and taken it one step further – by a commitment to funding research on a national level for the first time.
MOCA has joined several other leading ovarian cancer organizations in this week’s announcement of Stand Up To Cancer’s (SU2C) Ovarian Cancer Dream Team, which will begin research this July.
Funded by contributions from a groundbreaking collaboration of the nation’s ovarian cancer organizations, the Ovarian Cancer Dream Team will research therapies that target DNA repair, as well as a new method to identify, counsel and prevent the development of ovarian cancer in women with a high genetic risk of developing it.
The SU2C Dream Team is being funded for 3 years with $6 million from the Ovarian Cancer Research Fund, the Ovarian Cancer National Alliance and the National Ovarian Cancer Coalition, with contributions from organizations throughout the United States, including a $100,000 commitment from MOCA.
MOCA has provided more than $5 million to ovarian cancer research in Minnesota, making the organization one of the largest private, non-profit funders of ovarian cancer research in the nation.
“MOCA has always had an emphasis on research funding, as we know it is the only way we’ll make real progress against ovarian cancer,” said Kathleen Gavin, MOCA executive director. “By providing funding to the Ovarian Cancer Dream Team, we are further strengthening our commitment to the research community and funding a strong collaborative team who are focused on new ways to reach those at high risk and to prevent and treat this disease. This research will benefit women here in Minnesota and nationwide.”
MOCA’s executive director was also selected to serve as one of three advocates on the newly formed Team. Along with Gavin, Jamie Crase, an ovarian cancer survivor and Sue Friedman of Facing our Risk of Cancer Empowered (FORCE) will be working to represent the needs and interests of ovarian cancer patients and families and serving to connect the scientific and advocacy community.
Alan D’Andrea, MD, co-director of the Gene Therapy Center at Dana-Farber Cancer Institute in Boston, and the Fuller-American Cancer Society professor of medicine at Harvard Medical School, will lead the Dream Team. Elizabeth M. Swisher, MD, professor in the Department of Obstetrics and Gynecology at the University of Washington in Seattle, will be co-leader.
In addition to the team leaders, the project will involve researchers at Mayo Clinic in Rochester, Minnesota; University of Chicago; The University of Texas MD Anderson Cancer Center in Houston; and Memorial Sloan Kettering Cancer Center in New York.
Because researchers and clinicians from Mayo Clinic are on the team, Minnesota women will have access to clinical trials and screening and prevention strategies undertaken by the team. If you would like to learn more about the projects, call the MOCA office at (612) 822-0500.
Stay tuned for continued updates from MOCA on the SU2C Ovarian Cancer Dream Team efforts.